CTOs on the Move

Garden of Life, Inc.

www.gardenoflife.com

 
Garden of Life, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in West Palm Beach, FL. To find more information about Garden of Life, Inc., please visit www.gardenoflife.com
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.gardenoflife.com
  • 5500 Village Blvd Ste 202
    West Palm Beach, FL USA 33407-1961
  • Phone: 561.748.2477

Executives

Name Title Contact Details

Similar Companies

MyHealth Centre

MyHealth Centre is a unique collaborative partnership of medical professionals and health care industry experts established in order to deliver quality and innovation in patient care. MyHealth Centre is a leading manager of independently owned diagnostic imaging facilities in Ontario. We currently manage over 25 Independent Health Facilities (IHFs) with agreements to develop additional IHF licenses.

Cirrus Health

Cirrus Health is an organization uniquely qualified to successfully adapt to the ever-changing healthcare environment. While the complexity of today's healthcare creates barriers for some companies, it is a market of opportunities for Cirrus Health.

Implantable Provider Group

IPG works with top national and regional commercial payers, as well as various manufacturers in the cardiovascular, neurological and orthopedic spaces.

ControlRad Systems

ControlRad is a privately-held medical technology company developing innovative products that dramatically reduce the lifetime risk of radiation exposure from fluoroscopically guided interventional procedures (FGIP) for patients and healthcare professionals.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.